Literature DB >> 19036113

Long-term follow-up of a population based cohort with monoclonal proteinaemia.

Cees G Schaar1, Saskia le Cessie, Simone Snijder, Paul F H Franck, Pierre W Wijermans, Cisca Ong, Hanneke Kluin-Nelemans.   

Abstract

Prospective studies on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance (MGUS) and factors predictive of survival are lacking. The Dutch Comprehensive Cancer Centre West, comprising 1.6 million inhabitants, initiated a prospective hospital-based cohort study on 1464 patients with newly diagnosed M-proteinaemia, median age 73 (17-103) years. M-protein related diagnoses, patients' characteristics, laboratory investigations, bone marrow examinations and skeletal X-rays were registered with a yearly follow-up. Main endpoints were death, or new diagnoses of multiple myeloma and non-Hodgkin lymphoma. Kaplan-Meier survival curves were compared with age- and gender-matched survival data from the total Dutch population. Cumulative malignant transformation was corrected for death using a competing risk model. Risk factors for transformation or death were analyzed by univariate and multivariate analyses. In 1007 MGUS-patients, malignant transformation was associated with rising M-protein levels, IgA and IgM isotype and occurred at a yearly rate of 0.4%. All MGUS patients survived less than a matched cohort of the Dutch population, even in the absence of M-protein-associated comorbidity. Serum albumin levels at entry appeared highly predictive for survival. M-proteinaemia is not an innocent symptom. Although malignant transformation occurs rarely, survival is shortened irrespective of comorbidity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036113     DOI: 10.1111/j.1365-2141.2008.07423.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

Review 1.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

2.  The significance of monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Shaji Kumar
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

3.  Risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies: determining demographic differences in the USA.

Authors:  Ronald S Go; Herbert C Heien; Lindsey R Sangaralingham; Elizabeth B Habermann; Nilay D Shah
Journal:  Haematologica       Date:  2017-12-21       Impact factor: 9.941

4.  Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Therese M-L Andersson; Sandra Eloranta; Paul W Dickman; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

5.  A Single-Center Retrospective Study to Investigate the Follow-Up of Patients with Monoclonal Proteinemia by Community Physicians in the UK.

Authors:  Indra Ramasamy
Journal:  J Blood Med       Date:  2020-06-11

Review 6.  Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis.

Authors:  Xiaoxue Wang; Yan Li; Xiaojing Yan
Journal:  Biomed Res Int       Date:  2016-02-01       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.